Abstract:Although sex could affect the adaptive antitumor immunity, whether it had impact on the efficacy of first‐line PD‐1 blockade plus chemotherapy in advanced NSCLC remained undetermined. This study reported that female patients with advanced NSCLC would derive a larger benefit from first‐line PD‐1 blockade plus chemotherapy than male patients. Pretreatment tumor tissues from female patients had markedly lower tumor mutation and neoantigen burden, but significantly higher CD4, CD4/FOXP3, and CD4/FOXP3/PD‐L1 expression level than male patients, suggesting sex‐based neoantigen burden and immune microenvironmental feature heterogeneity would orchestrate the response to first‐line PD‐1 blockade plus chemotherapy in advanced NSCLC. Background To investigate the sex‐based heterogeneity of immune microenvironmental feature and its impact on the response to first‐line PD‐1 blockade plus chemotherapy in patients with driver‐negative advanced or metastatic non‐small‐cell lung cancer (NSCLC). Patients and Methods A total of 439 patients with advanced NSCLC treated with first‐line PD‐1 blockade plus chemotherapy or chemotherapy were identified. Differences in clinical outcomes between female and male patients were determined using Kaplan–Meier curves. Neoantigen burden and five immune microenvironmental markers expression including PD‐L1, CD4, CD8, FOXP3, and CD68 were compared between two groups. Results Of 175 eligible patients, 89 received PD‐1 blockade plus chemotherapy and 86 received first‐line chemotherapy. Forty five were women (25.7%) and 130 were men (74.3%). Female patients received first‐line PD‐1 blockade in combination with chemotherapy had dramatically better ORR (85.2% vs. 53.2%; p = 0.009), PFS (23.7 vs. 7.3 months; p = 0.013), and OS (46.2 vs. 20.0 months; p = 0.004) than males. Treatment outcomes were similar between females and males in chemotherapy group. Multivariate analyses showed that sex was the independent prognostic factor for patients received PD‐1 blockade combined with chemotherapy. Although female patients had significantly lower tumor mutational and neoantigen burden than males, pretreatment tumor tissues of female patients had markedly higher CD4, CD4/FOXP3, and CD4/FOXP3/PD‐L1 expression level than male patients. Conclusions Female patients with untreated advanced or metastatic NSCLC would derive a larger benefit from PD‐1 blockade in combination with chemotherapy than males. The biological significances of heterogeneity of tumor immune microenvironmental features between them need further investigation.

Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity

Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang

Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells

Androgen conspires with the CD8 + T cell exhaustion program and contributes to sex bias in cancer

Supplementary Table 2 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Antiandrogen Treatment Induces Stromal Cell Reprogramming to Promote Castration Resistance in Prostate Cancer

Sex-associated Molecular Differences for Cancer Immunotherapy

Sex differences in renal cell carcinoma: a single-cell analysis reveals exhausted CD8+ T-cells highly infiltrated in males

Comprehensive Characterization of Tumor Microenvironment Differences in Cancer between Male and Female Patients

Connecting the Mechanisms of Tumor Sex Differences with Cancer Therapy.

Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment.

Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes

Downregulating Testosterone Levels Enhance Immunotherapy Efficiency

T-cell expression of CXCL13 is associated with immunotherapy response in a sex-dependent manner in patients with lung cancer

Supplementary Table 5 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Supplementary Table 4 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Sex Differences in Genomic Features of Hepatitis B-Associated Hepatocellular Carcinoma With Distinct Antitumor Immunity

Sex‐based immune microenvironmental feature heterogeneity in response to PD‐1 blockade in combination with chemotherapy for patients with untreated advanced non‐small‐cell lung cancer

Somatic Mutational Landscape Reveals Mutational Signatures and Significantly Mutated Genes of Cancer Immunotherapeutic Outcome and Sex Disparities

An Integrative Study to Investigate Sex-Specific Biomarkers in Bladder Cancer Patients